Compare Li Auto Inc (LI) vs TransMedics Group Inc (TMDX) Price & Performance

Li Auto (LI) trades at $12.505, down 2.61% on the day, with a bearish technical signal and mixed earnings performance. Recent quarterly results show misses on EPS estimates, while revenue declined to $112.31 billion in 2025. The company maintains strong delivery growth, with 30,468 vehicles delivered in July 2026, but faces intense competition in China's EV market. Cash flow trends indicate operational challenges, with negative net cash flow of $9.00 billion in 2025.

Outlook remains cautious due to profitability pressures and competitive headwinds, though analyst consensus suggests moderate upside to a $14.80 price target. Key risks include execution on new model launches and macroeconomic volatility in the EV sector. The stock's current valuation metrics, such as a P/S of 0.83, may appeal to value-oriented investors if operational improvements materialize.

TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.

Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.